Zhifei Biotech: Announcement on acceptance of clinical trial application for trivalent influenza virus lysis vaccine (ZFA02 adjuvant)
Zhifei Biotech: Announcement on optimizing and adjusting strategic cooperation with GSK
Zhifei Biotech: Announcement on the Continued Inclusion of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) in the National Medical Insurance Catalogue
Zhifei Biotech: Announcement on acceptance of the application for production registration of the influenza virus lysis vaccine
Zhifei Biotech: Announcement on the approval notice for the quadrivalent influenza virus lysis vaccine (ZFA02 adjuvant) for clinical trials
Zhifei Biotech: Announcement on acceptance of the application for production registration for freeze-dried human rabies vaccine (human diploid cells)
Zhifei Biotech: Announcement on acceptance of the application for production registration of the quadrivalent influenza virus lysis vaccine (pediatric type)
Zhifei Biotech: Announcement on the completion of the Board of Directors and Supervisory Board changes and the departure of some directors and senior management at the end of their term
Zhifei Biotech: Legal Opinion of Beijing Jindu (Chongqing) Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Chongqing Zhifei Biological Products Co., Ltd.
Zhifei Biotech: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Zhifei Biotech: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Zhifei Biotech: Announcement on the Election of Staff Representative Supervisors for the 6th Board of Supervisors
Zhifei Biotech: Summary table of non-operating capital occupation and other related capital transactions for the first half year of 2024
Zhifei Biotech: Opinions of the Nomination Committee of the 5th Board of Directors of the Company on the qualifications of candidates for the 6th board of directors
Chongqing Zhifei Biological Products: Announcement regarding the entry of the 26-valent pneumococcal conjugate vaccine into phase I/II clinical trials.
Chongqing Zhifei Biological Products: Announcement regarding the withdrawal of the registration application for quadrivalent influenza virus split vaccines (vials packaging) by the company.
Chongqing Zhifei Biological Products: Announcement on the acceptance of clinical trial application for Quadrivalent Influenza Virus Split Vaccine (ZFA02 Adjuvant).
Chongqing Zhifei Biological Products: Announcement on the phase III clinical trial of quadrivalent recombinant Norovirus vaccine.
Chongqing Zhifei Biological Products: Legal Opinion of King & Wood Mallesons (Chongqing) Law Firm on the 2023 Shareholders' Meeting of Chongqing Zhifei Biological Products Co., Ltd. in Beijing
Chongqing Zhifei Biological Products: Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023